Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer (Q33710548)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer |
scientific article |
Statements
1 reference
Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer (English)
1 reference
Takayuki Yoshino
1 reference
Atsushi Ohtsu
1 reference
Satoshi Yuki
1 reference
Kentaro Yamazaki
1 reference
Nozomu Machida
1 reference
Ichinosuke Hyodo
1 reference
Yoshito Komatsu
1 reference
Takahide Sasaki
1 reference
Yutaka Yachi
1 reference
Hiroshi Onuma
1 reference
15 December 2013
1 reference
1 reference
32
1 reference
473-480
1 reference
15 December 2013
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference